Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENT-03S in Obesity and Type 2 Diabetes
NCT05925920Phase 1Completed
- Sponsor
- Metabolics Pharma, Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ENT-03S in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Metabolics Pharma, Inc. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 14 days and Safety and Tolerability of ENT-03 at 8 days. Started Jun 2023; status: completed.
02
Drugs
ENT-03S
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05925920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925920.